6.
Balmanno K, Chell S, Gillings A, Hayat S, Cook S
. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer. 2009; 125(10):2332-41.
DOI: 10.1002/ijc.24604.
View
7.
Mandal R, Becker S, Strebhardt K
. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene. 2015; 35(20):2547-61.
DOI: 10.1038/onc.2015.329.
View
8.
Valpione S, Carlino M, Mangana J, Mooradian M, McArthur G, Schadendorf D
. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. Eur J Cancer. 2018; 91:116-124.
DOI: 10.1016/j.ejca.2017.12.007.
View
9.
Fernandez M, DiMattia G, Dawson A, Bamford S, Anderson S, Hennessy B
. Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. Am J Cancer Res. 2016; 6(10):2235-2251.
PMC: 5088288.
View
10.
Grisham R, Sylvester B, Won H, McDermott G, DeLair D, Ramirez R
. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol. 2015; 33(34):4099-105.
PMC: 4669594.
DOI: 10.1200/JCO.2015.62.4726.
View
11.
Monk B, Grisham R, Banerjee S, Kalbacher E, Mirza M, Romero I
. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020; 38(32):3753-3762.
PMC: 7655017.
DOI: 10.1200/JCO.20.01164.
View
12.
Slomovitz B, Gourley C, Carey M, Malpica A, Shih I, Huntsman D
. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020; 156(3):715-725.
DOI: 10.1016/j.ygyno.2019.12.033.
View
13.
Farley J, Brady W, Vathipadiekal V, Lankes H, Coleman R, Morgan M
. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2012; 14(2):134-40.
PMC: 3627419.
DOI: 10.1016/S1470-2045(12)70572-7.
View